Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation
To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. L...
Saved in:
Published in | The Journal of clinical investigation Vol. 105; no. 10; pp. 1473 - 1482 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Clinical Investigation
15.05.2000
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF(1alpha) (PGI-M) and 11-dehydro thromboxane B(2) (Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans. |
---|---|
AbstractList | To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF
1α
(PGI-M) and 11-dehydro thromboxane B
2
(Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF
2α
-III, iPF
2α
-VI, and 8,12-
iso
-iPF
2α
-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans. To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF(1alpha) (PGI-M) and 11-dehydro thromboxane B(2) (Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans.To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF(1alpha) (PGI-M) and 11-dehydro thromboxane B(2) (Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans. To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects placebo or bolus injections of lipopolysaccharide (LPS), which caused a dose-dependent increase in temperature, heart rate, and plasma cortisol. LPS caused also dose-dependent elevations in urinary excretion of 2,3-dinor 6-keto PGF(1alpha) (PGI-M) and 11-dehydro thromboxane B(2) (Tx-M). Platelet COX-1 inhibition by chronic administration of low-dose aspirin before LPS did not alter the symptomatic and febrile responses to LPS, but the increment in urinary PGI-M and Tx-M were both partially depressed. Pretreatment with ibuprofen, a nonspecific COX inhibitor, attenuated the febrile and systemic response to LPS and inhibited prostanoid biosynthesis. Both celecoxib, a selective COX-2 inhibitor, and ibuprofen attenuated the pyrexial, but not the chronotropic, response to LPS. Experimental endotoxemia caused differential expression of the COX isozymes in monocytes and polymorphonuclear leucocytes ex vivo. LPS also increased urinary iPF(2alpha)-III, iPF(2alpha)-VI, and 8,12-iso-iPF(2alpha)-VI, isoprostane (iP) indices of lipid peroxidation, and none of the drugs blunted this response. These studies indicate that (a) although COX-2 predominates, both COX isozymes are induced and contribute to the prostaglandin response to LPS in humans; (b) COX activation contributes undetectably to lipid peroxidation induced by LPS; and (c) COX-2, but not COX-1, contributes to the constitutional response to LPS in humans. |
Author | Burke, A. Lawson, J.A. Habib, A. Kapoor, S. McAdam, B.F. FitzGerald, G.A. Mardini, I.A. |
AuthorAffiliation | 1 Center for Experimental Therapeutics, 2 Department of Anesthesia, and 3 General Clinical Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA |
AuthorAffiliation_xml | – name: 1 Center for Experimental Therapeutics, 2 Department of Anesthesia, and 3 General Clinical Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA |
Author_xml | – sequence: 1 givenname: B.F. surname: McAdam fullname: McAdam, B.F. – sequence: 2 givenname: I.A. surname: Mardini fullname: Mardini, I.A. – sequence: 3 givenname: A. surname: Habib fullname: Habib, A. – sequence: 4 givenname: A. surname: Burke fullname: Burke, A. – sequence: 5 givenname: J.A. surname: Lawson fullname: Lawson, J.A. – sequence: 6 givenname: S. surname: Kapoor fullname: Kapoor, S. – sequence: 7 givenname: G.A. surname: FitzGerald fullname: FitzGerald, G.A. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10811855$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkU1LxDAQhnNQ_MZ_ID3pqdo0yTY9eJDFTwQveg6zyWSNtMmatOL66211_YTAkJln3hfe2SZrPngkZJ8Wx5RW5cnN9LoWJVsjW0VR0ryumNwk2yk9FQXlXPANskkLSakUYou8nVuLusuCzSLO-wY6NBm-LiKm5IIf-499Cz7TS92E8Lqco4eEmUvBhtimbGDQ6ZDAB2cy8GYc_eosYjC97kYtNz7bQNvC-N8l6xaahHurukMeLs7vp1f57d3l9fTsNtecFV0uhDUUJxYoIgfgzIqJ1UZobish9KyuRDXTFdOS48xyKq3VUpaSgakNk8B2yOmn7qKftWg0-i5CoxbRtRCXKoBTfyfePap5eFGMCj6ph_3D1X4Mzz2mTrUuaWwa8Bj6pCo6xF6VxQAe_Db6dvhKewDyT0DHkFJEq7TrPrIYfF0zgGq8oFpdcOCP_vE_kn_Jd1hcocI |
CitedBy_id | crossref_primary_10_2319_041118_273_1 crossref_primary_10_1034_j_1601_1546_2002_30104_x crossref_primary_10_1667_RR2771_1 crossref_primary_10_1016_j_prostaglandins_2013_04_003 crossref_primary_10_1038_nrd1225 crossref_primary_10_1016_j_cellsig_2015_01_014 crossref_primary_10_1002_ar_21078 crossref_primary_10_1016_j_bbrc_2012_07_137 crossref_primary_10_1021_jm040782x crossref_primary_10_1016_S1590_8658_03_00048_3 crossref_primary_10_1016_j_prostaglandins_2018_10_005 crossref_primary_10_3748_wjg_v12_i34_5473 crossref_primary_10_1172_JCI37098 crossref_primary_10_1073_pnas_061607398 crossref_primary_10_1111_j_1476_5381_2011_01486_x crossref_primary_10_3390_antiox11071340 crossref_primary_10_1186_1472_6882_13_134 crossref_primary_10_3390_ani13101597 crossref_primary_10_1096_fj_04_2330rev crossref_primary_10_1186_s12916_015_0394_4 crossref_primary_10_2217_clp_10_11 crossref_primary_10_1038_srep36987 crossref_primary_10_1177_039463200702000104 crossref_primary_10_1093_occmed_kqm109 crossref_primary_10_1097_01_LAB_0000041714_05322_C0 crossref_primary_10_1016_j_jpain_2006_10_004 crossref_primary_10_1016_j_prostaglandins_2012_08_006 crossref_primary_10_1016_j_placenta_2020_12_012 crossref_primary_10_1111_ahe_12520 crossref_primary_10_1111_eos_12722 crossref_primary_10_1016_j_ctim_2011_08_002 crossref_primary_10_1097_01_XEJ_0000417555_65230_8d crossref_primary_10_1111_j_1468_3083_2011_04229_x crossref_primary_10_1161_hc4101_097114 crossref_primary_10_1056_NEJM200108093450607 crossref_primary_10_1016_j_bios_2006_05_020 crossref_primary_10_1158_0008_5472_CAN_06_3952 crossref_primary_10_1016_j_niox_2011_07_002 crossref_primary_10_1161_01_CIR_0000093661_90582_c4 crossref_primary_10_1371_journal_ppat_1010040 crossref_primary_10_1161_CIRCRESAHA_114_301809 crossref_primary_10_1161_01_CIR_0000039341_57809_1E crossref_primary_10_1172_JCI200113416 crossref_primary_10_1172_JCI200113418 crossref_primary_10_1161_01_ATV_0000104005_92603_f2 crossref_primary_10_1161_JAHA_112_002923 crossref_primary_10_1157_13089104 crossref_primary_10_1160_TH16_10_0799 crossref_primary_10_3390_plants10122663 crossref_primary_10_1038_sj_bjp_0704019 crossref_primary_10_1097_TA_0b013e31806bf0ab crossref_primary_10_1002_ptr_2803 crossref_primary_10_1016_j_jdermsci_2008_09_010 crossref_primary_10_1016_j_bios_2010_09_009 crossref_primary_10_1194_jlr_R800094_JLR200 crossref_primary_10_4236_wjns_2014_42021 crossref_primary_10_1185_030079907X242584 crossref_primary_10_1124_mol_112_080762 crossref_primary_10_1080_07391102_2024_2310783 crossref_primary_10_1067_mob_2002_126864 crossref_primary_10_1159_000381137 crossref_primary_10_1111_j_1572_0241_2002_05427_x crossref_primary_10_1016_j_plipres_2010_07_005 crossref_primary_10_1016_j_pharmthera_2005_02_004 crossref_primary_10_1073_pnas_0702279104 crossref_primary_10_1152_ajplung_00218_2015 crossref_primary_10_1128_microbiolspec_MCHD_0035_2016 crossref_primary_10_1016_j_arr_2018_09_004 crossref_primary_10_1161_ATVBAHA_110_207449 crossref_primary_10_1016_j_jaci_2011_01_065 crossref_primary_10_1002_anie_202003687 crossref_primary_10_1161_CIRCULATIONAHA_107_731398 crossref_primary_10_5796_electrochemistry_23_68121 crossref_primary_10_1111_j_1365_2036_2004_02037_x crossref_primary_10_1016_j_freeradbiomed_2004_10_024 crossref_primary_10_1194_jlr_R800042_JLR200 crossref_primary_10_1007_s12265_013_9529_1 crossref_primary_10_1152_ajpregu_90985_2008 crossref_primary_10_1152_ajpheart_00598_2001 crossref_primary_10_1016_j_intimp_2021_107778 crossref_primary_10_1016_j_yexcr_2012_07_021 crossref_primary_10_1172_JCI200318012 crossref_primary_10_3389_fphar_2018_00976 crossref_primary_10_1016_j_virol_2007_09_025 crossref_primary_10_2165_00002018_200326130_00001 crossref_primary_10_1161_01_CIR_0000043260_82447_62 crossref_primary_10_1016_j_jcmgh_2025_101469 crossref_primary_10_1124_jpet_300_2_393 crossref_primary_10_1074_jbc_M109_024075 crossref_primary_10_1111_j_1872_034X_2010_00727_x crossref_primary_10_1172_JCI23683 crossref_primary_10_1179_135100009X12525712409535 crossref_primary_10_1093_eurheartj_ehi016 crossref_primary_10_3390_ijms22020723 crossref_primary_10_1016_j_pain_2009_05_029 crossref_primary_10_1517_14728220903018932 crossref_primary_10_1172_JCI42545 crossref_primary_10_1073_pnas_012511599 crossref_primary_10_1080_10641963_2020_1817473 crossref_primary_10_1185_030079908X273066 crossref_primary_10_1172_JCI13375 crossref_primary_10_1089_ars_2007_1783 crossref_primary_10_1073_pnas_0404185101 crossref_primary_10_2460_ajvr_2004_65_1724 crossref_primary_10_1016_S1074_3804_05_60237_X crossref_primary_10_1210_jc_2006_2545 crossref_primary_10_1002_anie_201914845 crossref_primary_10_1016_j_jns_2013_10_004 crossref_primary_10_1016_S0006_8993_01_02707_X crossref_primary_10_1093_pm_pnv113 crossref_primary_10_3103_S0096392521020024 crossref_primary_10_1111_j_1462_5822_2005_00635_x crossref_primary_10_1111_j_1472_8206_2006_00435_x crossref_primary_10_1007_s11906_996_0001_3 crossref_primary_10_1016_j_carpath_2007_02_005 crossref_primary_10_1002_ange_202003687 crossref_primary_10_1172_JCI200113455 crossref_primary_10_1016_S0090_6980_02_00011_4 crossref_primary_10_1146_annurev_med_011209_153129 crossref_primary_10_2217_17460875_1_2_191 crossref_primary_10_1194_jlr_M036673 crossref_primary_10_2217_pgs_15_43 crossref_primary_10_1002_ange_201914845 crossref_primary_10_1007_s00238_011_0602_1 crossref_primary_10_1042_BJ20060615 crossref_primary_10_1021_acschembio_8b00584 crossref_primary_10_1155_2012_503128 crossref_primary_10_1074_jbc_M706839200 crossref_primary_10_1586_1744666X_4_3_339 crossref_primary_10_1002_cpt_794 crossref_primary_10_1002_elan_201300542 crossref_primary_10_1016_j_yexcr_2012_05_027 crossref_primary_10_1007_s10157_011_0492_3 crossref_primary_10_1007_s11655_016_2606_y crossref_primary_10_1016_j_ejphar_2021_174435 crossref_primary_10_1038_s41467_024_45174_6 crossref_primary_10_1097_01_blo_0000126337_65685_e4 crossref_primary_10_1016_S1567_5769_01_00204_1 crossref_primary_10_1007_s11033_010_0151_x crossref_primary_10_1016_j_febslet_2012_09_001 crossref_primary_10_1016_S0211_3449_05_73608_0 crossref_primary_10_1124_jpet_111_185405 crossref_primary_10_1074_jbc_M608975200 crossref_primary_10_1016_j_joca_2004_05_002 crossref_primary_10_1089_can_2022_0008 crossref_primary_10_1161_01_CIR_0000143234_51796_A9 crossref_primary_10_1016_j_thromres_2007_12_011 crossref_primary_10_1038_srep42683 |
Cites_doi | 10.1074/jbc.273.45.29295 10.1001/jama.282.20.1921 10.4049/jimmunol.160.3.1402 10.1126/science.7701344 10.1073/pnas.93.19.10417 10.1161/01.CIR.76.1.6 10.1073/pnas.91.25.12013 10.1016/S0022-3565(24)37166-6 10.1073/pnas.96.23.13381 10.1016/S0021-9258(19)49483-0 10.1161/01.CIR.95.11.2492 10.1161/01.CIR.80.6.1718 10.1182/blood.V76.12.2520.2520 10.1016/0091-6749(90)90219-T 10.1016/S0021-9258(18)53338-X 10.1073/pnas.91.8.3228 10.1074/jbc.271.15.8919 10.1056/NEJM199703273361303 10.1074/jbc.270.17.9800 10.1172/JCI117060 10.1016/0024-3205(79)90507-1 10.1172/JCI3985 10.1074/jbc.274.16.10689 10.1001/jama.282.20.1929 10.1016/S0021-9258(18)52976-8 10.1073/pnas.88.7.2692 10.1016/S0171-2985(11)80353-0 10.1001/archsurg.1988.01400260042004 10.1056/NEJM198404263101701 10.1074/jbc.271.52.33157 10.1016/S0021-9258(18)42073-X 10.1161/01.CIR.73.6.1300 10.1073/pnas.85.2.304 10.1161/01.CIR.67.6.1174 10.1056/NEJM199405053301808 10.1016/S0021-9258(19)38515-1 10.1038/26233 10.1016/S0002-9440(10)65230-3 10.1126/science.1698311 10.1016/S0049-3848(98)00179-0 10.1097/00000658-198908000-00018 10.1096/fasebj.5.9.1907252 10.1016/0049-3848(87)90103-4 10.1074/jbc.274.35.24441 10.1016/S0022-3565(24)38195-9 10.1096/fasebj.12.12.1063 10.1016/0005-2760(94)00196-6 10.1182/blood.V89.5.1621 10.1161/01.CIR.94.1.19 10.1172/JCI116971 10.1016/0006-291X(92)91313-F 10.1161/01.ATV.14.7.1021 10.1073/pnas.95.7.3449 10.1016/0092-8674(95)90125-6 10.1172/JCI114850 10.1128/CMR.8.2.268 10.1152/ajpcell.1994.267.4.C1067 10.1152/jappl.1992.73.3.925 10.1161/01.CIR.71.3.434 10.1161/01.RES.84.2.193 10.1126/science.2402637 10.1038/26239 10.1093/infdis/164.3.599 10.1056/NEJM198610163151602 10.1073/pnas.96.1.272 10.1016/0092-8674(95)90126-4 10.1038/41780 10.1164/ajrccm/144.5.1095 10.1074/jbc.270.29.17273 10.1073/pnas.76.9.4350 10.1152/jappl.1993.74.6.3027 10.1016/0005-2760(94)00197-7 |
ContentType | Journal Article |
Copyright | Copyright © 2000, American Society for Clinical Investigation 2000 |
Copyright_xml | – notice: Copyright © 2000, American Society for Clinical Investigation 2000 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1172/JCI9523 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 1482 |
ExternalDocumentID | PMC315469 10811855 10_1172_JCI9523 |
Genre | Controlled Clinical Trial Research Support, U.S. Gov't, P.H.S Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCRR NIH HHS grantid: M01 RR000040 – fundername: NHLBI NIH HHS grantid: P50 HL054500 – fundername: NIGMS NIH HHS grantid: T32 GM007612 – fundername: NIGMS NIH HHS grantid: T32-GM07612 – fundername: NCRR NIH HHS grantid: MO 1RR00040 – fundername: NHLBI NIH HHS grantid: HL 54500 |
GroupedDBID | --- -~X .55 .GJ .XZ 08G 08P 29K 2WC 354 3O- 53G 5GY 5RE 5RS 8F7 AAWTL AAYOK AAYXX ABOCM ABPMR ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFCHL AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ASPBG AVWKF AZFZN BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB EX3 F5P FRP GROUPED_DOAJ GX1 HYE H~9 IAO IEA IHR INH IOF IPO J5H KQ8 L7B M1P M5~ MVM N4W OBH OCB ODZKP OFXIZ OGEVE OHH OK1 OVD OVIDX OVT P2P P6G RPM TEORI TR2 TVE UHU VH1 VVN W2D WH7 WOQ WOW X7M XSB YFH YHG YKV YOC ZGI ZXP ZY1 ~H1 36B 3V. 7RV 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAKAS ABUWG ADZCM AFKRA BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CGR CUY CVF EBD ECM EIF EMOBN FEDTE FYUFA HCIFZ HMCUK HVGLF IHW INR IOV ISR ITC LK8 M0L M7P NAPCQ NPM OHT PKN PQQKQ PROAC PSQYO Q2X S0X SJFOW SV3 UKHRP 7X8 5PM |
ID | FETCH-LOGICAL-c430t-55fd1e6fa1ee4aa43f56fcd5c4f755cb9757bc73c84ebf418ffc88283ad9d38a3 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 18:15:20 EDT 2025 Fri Jul 11 16:52:55 EDT 2025 Wed Feb 19 02:08:36 EST 2025 Thu Apr 24 22:56:44 EDT 2025 Tue Jul 01 03:48:39 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c430t-55fd1e6fa1ee4aa43f56fcd5c4f755cb9757bc73c84ebf418ffc88283ad9d38a3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Address correspondence to: Garret A. FitzGerald, Center for Experimental Therapeutics, University of Pennsylvania, 811 BRB II/III, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104-6160, USA. Phone: (215) 898-1185; Fax: (215) 573-9135; E-mail: garret@spirit.gcrc.upenn.edu. |
OpenAccessLink | http://www.jci.org/articles/view/9523/files/pdf |
PMID | 10811855 |
PQID | 71117720 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_315469 proquest_miscellaneous_71117720 pubmed_primary_10811855 crossref_citationtrail_10_1172_JCI9523 crossref_primary_10_1172_JCI9523 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20000515 |
PublicationDateYYYYMMDD | 2000-05-15 |
PublicationDate_xml | – month: 5 year: 2000 text: 20000515 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 2000 |
Publisher | American Society for Clinical Investigation |
Publisher_xml | – name: American Society for Clinical Investigation |
References | Xie (B8) 1991; 88 Rimarachin (B72) 1994; 14 van der Poll (B46) 1991; 164 FitzGerald (B25) 1983; 67 Kerins (B76) 1989; 80 Richardson (B60) 1989; 210 FitzGerald (B54) 1979; 25 Bernard (B22) 1997; 336 FitzGerald (B68) 1984; 310 Morham (B50) 1995; 83 Delanty (B77) 1997; 95 Patrono (B51) 1994; 330 Revhaug (B21) 1998; 123 Roy (B67) 1985; 71 Fitzgerald (B70) 1986; 315 Smith (B5) 1996; 271 Topper (B73) 1996; 93 Mallat (B29) 1999; 103 Li (B33) 1999; 96 O’Sullivan (B61) 1992; 267 B74 Geisel (B75) 1994; 267 Chow (B43) 1999; 274 Martich (B20) 1992; 73 B34 Praticò (B31) 1995; 270 Schumann (B40) 1990; 249 Wennmalm (B66) 1988; 255 Bernard (B19) 1991; 144 Masferrer (B10) 1994; 270 Dubois (B2) 1998; 12 van Deventer (B18) 1990; 76 Boujoukos (B59) 1993; 74 Hurley (B58) 1995; 8 B1 Reilly (B79) 1996; 94 Towbin (B36) 1979; 76 Habib (B57) 1993; 268 Funk (B4) 1991; 5 Catella-Lawson (B35) 1999; 289 Hempel (B44) 1994; 93 Jun (B62) 1999; 84 Maloney (B65) 1998; 160 Lawson (B26) 1999; 35 Yang (B42) 1998; 395 Crofford (B64) 1994; 93 Zhang (B13) 1997; 283 Schonbeck (B63) 1999; 155 Reilly (B69) 1986; 73 Maier (B71) 1990; 265 Kujubu (B7) 1993; 268 Langman (B48) 1999; 282 Niiro (B9) 1997; 89 Praticò (B30) 1998; 95 Martich (B16) 1993; 187 Ushikubi (B52) 1998; 395 Christ (B39) 1995; 268 Smith (B3) 1992; 263 Catella (B23) 1987; 47 Wright (B41) 1990; 249 Cassale (B17) 1990; 85 Simon (B47) 1999; 282 Harrison (B28) 1995; 29 Nowak (B78) 1987; 76 Masferrer (B12) 1994; 91 Creminon (B37) 1995; 1254 Langenbach (B49) 1995; 83 Creminon (B38) 1995; 1254 Wendelborn (B27) 1999; 85 Masferrer (B56) 1990; 86 Praticó (B45) 1996; 271 Seibert (B11) 1994; 91 Salat (B55) 1999; 93 Masferrer (B15) 1990; 86 Lawson (B32) 1998; 273 Murata (B53) 1997; 388 McAdam (B24) 1999; 96 O’Sullivan (B14) 1992; 187 Jones (B6) 1993; 268 |
References_xml | – volume: 273 start-page: 29295 year: 1998 ident: B32 publication-title: J Biol Chem doi: 10.1074/jbc.273.45.29295 – volume: 282 start-page: 1921 year: 1999 ident: B47 publication-title: JAMA doi: 10.1001/jama.282.20.1921 – volume: 263 start-page: F181 year: 1992 ident: B3 publication-title: Am J Physiol – volume: 160 start-page: 1402 year: 1998 ident: B65 publication-title: J Immunol doi: 10.4049/jimmunol.160.3.1402 – volume: 268 start-page: 80 year: 1995 ident: B39 publication-title: Science doi: 10.1126/science.7701344 – volume: 93 start-page: 10417 year: 1996 ident: B73 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.19.10417 – volume: 76 start-page: 6 year: 1987 ident: B78 publication-title: Circulation doi: 10.1161/01.CIR.76.1.6 – volume: 91 start-page: 12013 year: 1994 ident: B11 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.91.25.12013 – volume: 283 start-page: 1069 year: 1997 ident: B13 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)37166-6 – volume: 96 start-page: 13381 year: 1999 ident: B33 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.23.13381 – volume: 268 start-page: 23448 year: 1993 ident: B57 publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)49483-0 – volume: 95 start-page: 2492 year: 1997 ident: B77 publication-title: Circulation doi: 10.1161/01.CIR.95.11.2492 – volume: 80 start-page: 1718 year: 1989 ident: B76 publication-title: Circulation doi: 10.1161/01.CIR.80.6.1718 – volume: 76 start-page: 2520 year: 1990 ident: B18 publication-title: Blood doi: 10.1182/blood.V76.12.2520.2520 – volume: 85 start-page: 45 year: 1990 ident: B17 publication-title: J Allergy Clin Immunol doi: 10.1016/0091-6749(90)90219-T – volume: 268 start-page: 5425 year: 1993 ident: B7 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)53338-X – volume: 91 start-page: 3228 year: 1994 ident: B12 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.91.8.3228 – volume: 271 start-page: 8919 year: 1996 ident: B45 publication-title: J Biol Chem doi: 10.1074/jbc.271.15.8919 – volume: 336 start-page: 912 year: 1997 ident: B22 publication-title: N Engl J Med doi: 10.1056/NEJM199703273361303 – volume: 270 start-page: 9800 year: 1995 ident: B31 publication-title: J Biol Chem doi: 10.1074/jbc.270.17.9800 – volume: 93 start-page: 1095 year: 1994 ident: B64 publication-title: J Clin Invest doi: 10.1172/JCI117060 – volume: 25 start-page: 665 year: 1979 ident: B54 publication-title: Life Sci doi: 10.1016/0024-3205(79)90507-1 – volume: 103 start-page: 421 year: 1999 ident: B29 publication-title: J Clin Invest doi: 10.1172/JCI3985 – volume: 274 start-page: 10689 year: 1999 ident: B43 publication-title: J Biol Chem doi: 10.1074/jbc.274.16.10689 – volume: 282 start-page: 1929 year: 1999 ident: B48 publication-title: JAMA doi: 10.1001/jama.282.20.1929 – volume: 268 start-page: 9049 year: 1993 ident: B6 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)52976-8 – volume: 88 start-page: 2692 year: 1991 ident: B8 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.88.7.2692 – volume: 187 start-page: 403 year: 1993 ident: B16 publication-title: Immunobiology doi: 10.1016/S0171-2985(11)80353-0 – volume: 123 start-page: 162 year: 1998 ident: B21 publication-title: Arch Surg doi: 10.1001/archsurg.1988.01400260042004 – volume: 310 start-page: 1065 year: 1984 ident: B68 publication-title: N Engl J Med doi: 10.1056/NEJM198404263101701 – volume: 271 start-page: 33157 year: 1996 ident: B5 publication-title: J Biol Chem doi: 10.1074/jbc.271.52.33157 – volume: 267 start-page: 14547 year: 1992 ident: B61 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)42073-X – volume: 73 start-page: 1300 year: 1986 ident: B69 publication-title: Circulation doi: 10.1161/01.CIR.73.6.1300 – volume: 85 start-page: 304 year: 1999 ident: B27 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.85.2.304 – volume: 67 start-page: 1174 year: 1983 ident: B25 publication-title: Circulation doi: 10.1161/01.CIR.67.6.1174 – volume: 330 start-page: 1287 year: 1994 ident: B51 publication-title: N Engl J Med doi: 10.1056/NEJM199405053301808 – volume: 265 start-page: 10805 year: 1990 ident: B71 publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)38515-1 – ident: B34 – volume: 395 start-page: 281 year: 1998 ident: B52 publication-title: Nature doi: 10.1038/26233 – volume: 155 start-page: 1281 year: 1999 ident: B63 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65230-3 – volume: 249 start-page: 1431 year: 1990 ident: B41 publication-title: Science doi: 10.1126/science.1698311 – volume: 93 start-page: 145 year: 1999 ident: B55 publication-title: Thromb Res doi: 10.1016/S0049-3848(98)00179-0 – volume: 255 start-page: H15 year: 1988 ident: B66 publication-title: Am J Physiol – volume: 210 start-page: 239 year: 1989 ident: B60 publication-title: Ann Surg doi: 10.1097/00000658-198908000-00018 – volume: 270 start-page: 1340 year: 1994 ident: B10 publication-title: J Pharmacol Exp Ther – volume: 5 start-page: 2304 year: 1991 ident: B4 publication-title: FASEB J doi: 10.1096/fasebj.5.9.1907252 – volume: 47 start-page: 647 year: 1987 ident: B23 publication-title: Thromb Res doi: 10.1016/0049-3848(87)90103-4 – volume: 35 start-page: 24441 year: 1999 ident: B26 publication-title: J Biol Chem doi: 10.1074/jbc.274.35.24441 – volume: 289 start-page: 735 year: 1999 ident: B35 publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)38195-9 – ident: B1 – volume: 12 start-page: 1063 year: 1998 ident: B2 publication-title: FASEB J doi: 10.1096/fasebj.12.12.1063 – volume: 1254 start-page: 333 year: 1995 ident: B37 publication-title: Biochim Biophys Acta doi: 10.1016/0005-2760(94)00196-6 – volume: 89 start-page: 1621 year: 1997 ident: B9 publication-title: Blood doi: 10.1182/blood.V89.5.1621 – volume: 94 start-page: 19 year: 1996 ident: B79 publication-title: Circulation doi: 10.1161/01.CIR.94.1.19 – volume: 93 start-page: 391 year: 1994 ident: B44 publication-title: J Clin Invest doi: 10.1172/JCI116971 – volume: 187 start-page: 1123 year: 1992 ident: B14 publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(92)91313-F – volume: 14 start-page: 1021 year: 1994 ident: B72 publication-title: Arterioscler Thromb doi: 10.1161/01.ATV.14.7.1021 – volume: 95 start-page: 3449 year: 1998 ident: B30 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.7.3449 – volume: 83 start-page: 473 year: 1995 ident: B50 publication-title: Cell doi: 10.1016/0092-8674(95)90125-6 – volume: 86 start-page: 1375 year: 1990 ident: B56 publication-title: J Clin Invest doi: 10.1172/JCI114850 – volume: 8 start-page: 268 year: 1995 ident: B58 publication-title: Clin Microbiol Rev doi: 10.1128/CMR.8.2.268 – volume: 267 start-page: C1067 year: 1994 ident: B75 publication-title: Am J Physiol doi: 10.1152/ajpcell.1994.267.4.C1067 – volume: 73 start-page: 925 year: 1992 ident: B20 publication-title: J Appl Physiol doi: 10.1152/jappl.1992.73.3.925 – volume: 71 start-page: 434 year: 1985 ident: B67 publication-title: Circulation doi: 10.1161/01.CIR.71.3.434 – volume: 84 start-page: 193 year: 1999 ident: B62 publication-title: Circ Res doi: 10.1161/01.RES.84.2.193 – volume: 249 start-page: 1429 year: 1990 ident: B40 publication-title: Science doi: 10.1126/science.2402637 – volume: 395 start-page: 284 year: 1998 ident: B42 publication-title: Nature doi: 10.1038/26239 – volume: 86 start-page: 1375 year: 1990 ident: B15 publication-title: J Clin Invest doi: 10.1172/JCI114850 – volume: 164 start-page: 599 year: 1991 ident: B46 publication-title: J Infect Dis doi: 10.1093/infdis/164.3.599 – volume: 315 start-page: 983 year: 1986 ident: B70 publication-title: N Engl J Med doi: 10.1056/NEJM198610163151602 – volume: 96 start-page: 272 year: 1999 ident: B24 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.1.272 – volume: 83 start-page: 483 year: 1995 ident: B49 publication-title: Cell doi: 10.1016/0092-8674(95)90126-4 – volume: 388 start-page: 678 year: 1997 ident: B53 publication-title: Nature doi: 10.1038/41780 – volume: 144 start-page: 1095 year: 1991 ident: B19 publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/144.5.1095 – volume: 29 start-page: 17273 year: 1995 ident: B28 publication-title: J Biol Chem doi: 10.1074/jbc.270.29.17273 – volume: 76 start-page: 4350 year: 1979 ident: B36 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.76.9.4350 – volume: 74 start-page: 3027 year: 1993 ident: B59 publication-title: J Appl Physiol doi: 10.1152/jappl.1993.74.6.3027 – ident: B74 – volume: 1254 start-page: 341 year: 1995 ident: B38 publication-title: Biochim Biophys Acta doi: 10.1016/0005-2760(94)00197-7 |
SSID | ssj0014454 |
Score | 2.1049073 |
Snippet | To examine the role of cyclooxygenase (COX) isozymes in prostaglandin formation and oxidant stress in inflammation, we administered to volunteer subjects... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1473 |
SubjectTerms | Adult Aspirin - pharmacology Celecoxib Cyclooxygenase 1 Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - pharmacology Eicosanoids - biosynthesis Female Humans Ibuprofen - pharmacology In Vitro Techniques Inflammation - etiology Inflammation - metabolism Isoenzymes - biosynthesis Lipid Peroxidation - drug effects Lipopolysaccharides - toxicity Male Membrane Proteins Oxidative Stress - drug effects Prostaglandin-Endoperoxide Synthases - biosynthesis Prostaglandins - biosynthesis Prostaglandins - urine Pyrazoles Sulfonamides - pharmacology |
Title | Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10811855 https://www.proquest.com/docview/71117720 https://pubmed.ncbi.nlm.nih.gov/PMC315469 |
Volume | 105 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvY_elu-lh7KU4sy3Jl8e0rDQd2VMLfQu6Mo_OLk0Cbf9B__WOLMWy08IuEEw4kYTw90U6R-cihD4lhTKcERalKs0jWmoTCWOzgImOM17yVAmbOzz_nh2d0uMzdjYa3failtYrMZE39-aV_A-qIANcbZbsPyDbDQoC-A74whMQhudfYexLD4O-d-mulAftUV_50FanB7Zn9PJanjfN1TUMBJvWXrVsrKraOgo0MGHJ66ZSzo2wbHqSC1cO1odDwoyBPr8ClD8D03p6bZdrWYUSHsHXP5dT5Ti4PzmchPNw4Gl7udTebDKdhGVRVK2_KIj21z6cyIs2Bxatr92lbHYJBElU5q6oS7cIx6zPtri3pibUXXbi92dbuPT-tT-3tWSPD2YlS0nY3jYu_a1dr4tFbK2gPF34jg_QwxQsjtY6n33rHFKUMl_Q283d5V_bjl98x6Fic8da2Q667WkxJ0_REw8TnjouPUMjXT9Hj-Y-wOIFunGUwo3BHaVwoJSVt5TCQ0rhDaUwtAkEwkApPKAUDpTClf0ESr1Ep4dfTw6OIn89RyQpiVcRY0YlOjM80ZpyTolhmZGKSWpyxqQoc5YLmRNZUC0MTQpjJNhzBeGqVKTg5BXaqZtav0FYQWtWSqlJbijozKBEF1QIGUuRMk7VGH3evNuF9LXr7RUq54st9MYIdw0vXLmWu00-bsBZwFJq_WO81s16ucgTG8GQxmP02kHVG6IAQ5yxMcoGIHYNbJH24S919aMt1k7ARsnK3T_P6y16HP4t79DO6nKt34PCuxIfWir-Bs8ttMQ |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+regulated+expression+of+human+cyclooxygenase+isoforms+on+eicosanoid+and+isoeicosanoid+production+in+inflammation&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=McAdam%2C+B.F.&rft.au=Mardini%2C+I.A.&rft.au=Habib%2C+A.&rft.au=Burke%2C+A.&rft.date=2000-05-15&rft.issn=0021-9738&rft.volume=105&rft.issue=10&rft.spage=1473&rft.epage=1482&rft_id=info:doi/10.1172%2FJCI9523&rft.externalDBID=n%2Fa&rft.externalDocID=10_1172_JCI9523 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |